Glucovance (glyburide/metformin)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

PREGNANCY AND BREASTFEEDING SAFETY:

  • Glucovance has not been adequately evaluated in pregnant women. Due to the lack of conclusive safety data, Glucovance should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Glucovance is classified as FDA pregnancy risk category B.
  • It is not known if Glucovance is excreted in breast milk. Due to the lack of safety data and the potential risk for hypoglycemia (low blood glucose) in nursing infants, use of Glucovance in nursing mothers is not recommended.

PREPARATIONS: Oral tablets: 1.25/250, 2.5/500, and 5/500 mg

STORAGE:

  • Tablets should be stored at room temperature, between 15 C and 30 C (59 F to 86 F).
  • Tablets should be dispensed and stored in an air- tight, light resistance container.

DRUG CLASS AND MECHANISM:

  • Glucovance (glyburide/metformin) is a combination antidiabetic medication containing glyburide and metformin. Glucovance is used to improve blood glucose (sugar) control in adults with type 2 diabetes mellitus.
  • Glyburide is a second generation oral sulfonylurea. It helps to lower blood glucose by stimulating the release of insulin, the hormone responsible for regulating blood glucose.
  • Metformin is an oral biguanide antidiabetic agent. It decreases the production of glucose in the liver, decreases the absorption of glucose by the intestines, and increases the uptake and use of blood glucose by cells throughout the body.
  • In clinical studies, glyburide/metformin therapy was observed to be superior in improving fasting plasma glucose, post-meal blood glucose, and HbA1c levels versus treatment with glyburide or metformin alone.
  • Glucovance was approved by the FDA in July, 2000.

REFERENCE: FDA Prescribing Information.

Medically Reviewed by a Doctor on 8/31/2016

Quick GuideDiabetes Diet: Healthy Meal Plans for Diabetes-Friendly Eating

Diabetes Diet: Healthy Meal Plans for Diabetes-Friendly Eating
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Diabetes Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors